Healthcare >> CEO Interviews >> January 10, 2001

Michael Wick – Telik Inc (telk)

Michael M. Wick, MD, PhD, Chairman and Chief Executive Officer, joined Telik, Inc. in December 1997 as Executive Vice President, Research and Development and a Director. From 1995 to 1997, he was Senior Vice President of Research for CV Therapeutics. Dr. Wick served as Executive Director of oncology/immunology drug discovery and clinical research at Lederle Laboratories, a division of American Cyanamid, from 1990 to 1995, and also directed the Cyanamid/Immunex joint oncology research program. He began his career at Harvard Medical School, where he served as an Associate Professor from 1981 to 1994 and Chief of the Melanoma Clinic and Laboratory of Molecular Dermatologic Oncology at the Dana Farber Cancer Institute from 1980 to 1992. Dr. Wick holds a PhD degree in Chemistry from Harvard University and an MD degree from Harvard Medical School. Profile
TWST: Could we start out with a history and a quick overview of Telik?

Dr. Wick: Telik is a biopharmaceutical company located in South San

Francisco, California, near the cluster of